This medication is commonly used for easing symptoms associated with chronic inflammatory or irritative states in the respiratory system, and is applied within therapeutic areas involving chronic, sustained management.

Montelair is generally used for the prophylaxis and chronic treatment of asthma, for allergic rhinitis (both seasonal and perennial), and for the prevention of exercise-induced bronchoconstriction (EIB). This medicine plays a role in managing symptoms that interfere with daily functioning, such as persistent wheezing, chest tightness, and allergic manifestations including nasal congestion and frequent sneezing. The core therapeutic benefit provides support that helps ease the overall symptom burden. The medication is applied across domains where additional symptomatic support is needed; it may assist with maintaining functional stability.

---

Quick Fact: Symptom Management Focus

Montelair is applied in clinical settings that involve recurrent or episodic symptom patterns, helping to manage asthma by supporting symptomatic relief and assisting with managing symptoms associated with episodic or fluctuating manifestations. It is also relevant in contexts marked by increased discomfort due to year-round or seasonal allergies. This contributes to improved comfort during periods of heightened symptoms.

Regulatory References

1. NIH MedlinePlus Drug Information on Montelukast

This section explains who is eligible to use Montelair (montelukast sodium), strictly according to official government regulatory documentation.

Contraindications

Montelair is contraindicated and must not be used by patients who have a known hypersensitivity (allergic reaction) to montelukast sodium or any of the product's inactive ingredients. The medicine is also not indicated for the treatment of acute asthma attacks (such as status asthmaticus).

Age-Related Eligibility

Indication	Minimum Approved Age
Chronic Asthma	12 months and older
Perennial Allergic Rhinitis	6 months and older
Seasonal Allergic Rhinitis	2 years and older
EIB Prevention	6 years and older

For indications such as EIB prevention, safety and effectiveness have not been established in children younger than the minimum approved age. Use in older adults requires no dosage adjustment.

Condition-Based Restrictions

• Hepatic and Renal Function: No dosage adjustment is recommended for patients with renal impairment or mild-to-moderate hepatic impairment. There are no data on patients with severe hepatic impairment.
• Formulation Restriction: The chewable tablets contain phenylalanine and are used with caution in patients with phenylketonuria (PKU).

Pregnancy and Lactation Status

Due to a lack of adequate human studies, Montelair should be used during pregnancy only if clearly needed. For nursing mothers, use is limited to when it is considered clearly essential.

Montelair Interactions with other medicines and products

Montelair (montelukast) is metabolized in the liver by specific enzymes, primarily CYP3A4 and CYP2C9. Understanding these metabolic pathways helps identify potential drug interactions. The most important clinical interaction involves drugs that are strong inducers of these hepatic enzymes.

For example, when co-administered with Phenobarbital, a potent enzyme inducer, the systemic exposure (AUC) of montelukast is decreased by approximately 40%. Healthcare providers should monitor for potentially reduced therapeutic effect of Montelair when co-administered with this and other strong enzyme-inducing medicines, such as Phenytoin or Rifampin.

Medicines with Documented Interaction Study Results	Summary of Interaction
Theophylline, Prednisone, Prednisolone, Oral Contraceptives (ethinyl estradiol/norethindrone 35/1), Warfarin, Digoxin	No clinically important effects on the pharmacokinetics of these medicines were found when co-administered with Montelair.
Aspirin / NSAIDs	Patients with known aspirin sensitivity should continue to avoid aspirin or non-steroidal anti-inflammatory agents while taking Montelair.

Montelair must not be abruptly substituted for inhaled or oral corticosteroids. Patients receiving systemic corticosteroid therapy should be monitored for eosinophilia and systemic vasculitis, which can sometimes occur upon reduction or withdrawal of the oral corticosteroid.

Selective CysLT1 Receptor Blockade

Montelair (Montelukast) operates as a selective competitive antagonist at the Cysteinyl Leukotriene Receptor Type 1 ( CysLT1). This molecular interaction prevents the endogenous inflammatory mediators, the cysteine leukotrienes ( LTC4, LTD4, and LTE4), from binding to and activating the receptor. This blockade directly modulates the resulting cellular activity triggered by these potent lipid signals within the respiratory tract.

---

Modulating Airway Smooth Muscle and Edema

The primary physiological consequence of CysLT1 antagonism is the alteration of airway smooth muscle contractility. By inhibiting the leukotriene-mediated signal, the drug contributes to the maintenance of a reduced contractile state in smooth muscle. Concurrently, this mechanism reduces leukotriene-mediated microvascular permeability, thereby limiting fluid extravasation into the tissue. The mechanism primarily contributes to a maintenance-focused physiological profile by regulating an upstream signal rather than direct downstream relaxation.

---

Dampening Chronic Airway Inflammatory Cascades

By blocking leukotriene signaling, the drug modifies the biological signals necessary to recruit and activate key inflammatory cells like eosinophils into the airway tissues. This sustained reduction in cellular infiltration modulates the balance of inflammatory mediators within the tissue and limits the chronic biological activity known to contribute to increased airway sensitivity.

How to Use Montelair (Montelukast)

Montelair (Montelukast) is administered orally and must be used exactly as prescribed, following dosage and timing instructions. The medication is available in several forms and strengths, which are matched to the patient’s age.

Dosing and Schedule

Patient Group	Recommended Daily Dose	Schedule
Adults & Adolescents (15+ years)	10 mg film-coated tablet	Once daily, preferably in the evening.
Pediatric Patients (6–14 years)	5 mg chewable tablet	Once daily, preferably in the evening.
Pediatric Patients (2–5 years)	4 mg chewable tablet or oral granules	Once daily, preferably in the evening.

For the prevention of Exercise-Induced Bronchoconstriction (EIB), a single dose must be taken at least two hours before exercise. A patient who is already taking Montelair daily for chronic use should not take an additional dose for EIB. No dosage adjustment is required for patients with mild-to-moderate liver impairment or renal impairment.

Administration and Handling

Montelair can be taken with or without food. If using the oral granules, the sachet must be opened and the contents administered directly into the mouth, or mixed with a spoonful of cold or room temperature soft food (such as applesauce) or 5 mL of breast milk/formula. The granules must be consumed within 15 minutes of opening the packet and must not be stored for later use. The chewable tablets must be chewed completely before swallowing.

If a dose is missed, the patient should skip the missed dose and resume the regular dosing schedule with the next dose; two doses must not be taken at the same time.

Research Evidence / Overview of Studies

Phase 3 Clinical Trials: Efficacy and Outcomes

A series of Phase 3 clinical trials, involving over 2,500 adult participants, evaluated whether there was an improvement in patient-reported symptoms over a 12-week period. Initial trials examined symptom changes over time in early-stage conditions. Researchers conducted preliminary laboratory studies, which explore the possibility of the drug binding to specific inflammatory pathways.

• Symptom Assessment: One multicenter study was studied to determine if there was a reduction in the incidence of flare-ups compared to placebo. The primary endpoint for this trial was a change in the established clinical severity score.
• Biomarker Analysis: An analysis of patient samples from the trial research observed an association between the intervention and biomarkers of disease activity at the 6-month mark. A history of liver issues was noted as a consideration in the study protocol's enrollment criteria.
• Long-term Data: Research has explored whether the combination was associated with changes in long-term quality of life.

Safety Profile and Tolerability

The overall safety review included pooled data from all registrational trials, which tracked events of interest. The safety profile observed in clinical trials was generally similar to that of placebo.

• Specific Patient Groups: Moderate renal impairment was an exclusion criterion for the program’s design. The Phase 3 program excluded pregnant individuals and those with uncontrolled hypertension.
• Drug Interactions: The studies also included preliminary investigations into potential pharmacokinetic interactions with common concurrent medications.

Key Studies & References

1. Montelukast: risk of mental disorders vs. efficacy – a meta-analysis

Common questions about Montelair (FAQ)

Q: What is Montelair used for?

Montelair (Montelukast) is approved to help manage symptoms associated with chronic asthma and allergic rhinitis (hay fever). It is categorized as a leukotriene receptor antagonist.

---

Q: How does Montelair work?

Montelair works by blocking substances in the body called leukotrienes. Leukotrienes can cause the narrowing of airways and other inflammation associated with asthma and allergic rhinitis.

---

Q: How long does it take for Montelair to start working?

In studies, the beneficial effects of Montelair on specific measures of asthma control were often observed within one day of starting treatment. However, the time until an individual notes a significant change may vary.

---

Q: Can Montelair replace my rescue inhaler?

No. Montelair is a long-term control medication. It is not intended to treat sudden asthma attacks and should not be used as a substitute for a fast-acting rescue inhaler.

---

Q: What are the common side effects of Montelair?

Common side effects reported in clinical trials include headache, stomach pain, and upper respiratory infection symptoms. Patients are encouraged to discuss potential side effects with a healthcare provider.

How to Store and Dispose of Montelair (Montelukast Sodium)

Montelair must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C (86 F). The medicine must be kept in its original package to ensure protection from light and moisture.

Mandatory Storage and Handling

• Child Safety: All formulations must be stored out of the sight and reach of children.
• Oral Granules: The full dose must be administered immediately—within 15 minutes—after opening the sachet; unused mixtures of granules and food must not be stored.

Disposal Instructions

All unused or expired Montelair should be disposed of in accordance with local requirements. The medicine is not typically recommended for flushing down the toilet, and local disposal procedures for household medical waste should be followed.